

# Momelotinib in VEXAS Syndrome

NCT07098936

---

<b>Status</b>	RECRUITING
<b>Phase</b>	Phase 2
<b>Sponsor</b>	Groupe Francophone des Myelodysplasies
<b>Enrollment</b>	57 participants

## Key Eligibility Criteria

---

### Inclusion (18)

- ECOG (Eastern Cooperative Oncology Group) performance status 0-2 at the time of screening
- Age ≥ 18 years
- Written informed consent
- Diagnosis of VEXAS (Vacuoles, E1 enzyme, X-linked, Autoinflammatory and Somatic) syndrome with UBA1 (Ubiquitin Like Modifier Activating Enzyme 1) mutation and clinically symptomatic disease requiring immunosuppressive treatment and at least 10mg/d of glucocorticoids
- Patients with uncontrolled symptoms related to VEXAS with prior treatment line(s) (including steroids)

... and 13 more (see full listing online)

### Exclusion (12)

- Patients with MDS (Myelodysplastic syndrome) scheduled for allogeneic stem cell transplant or high risk MDS according to IWG (International Working Group) 2023
- Patients who are or have been already treated with Janus Kinase (JAK) inhibitors for VEXAS syndrome or another indication
- Patients who are unable to receive a starting daily dose of momelotinib of at least 100 mg
- Subjects with any other active malignancies are not eligible, except for the following: adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, or other cancer from which subject has been disease-free for at least 3 years
- Uncontrolled congestive heart failure (New York Heart Association Classification 3 or 4), angina, myocardial infarction, cerebrovascular accident, coronary/peripheral artery bypass graft surgery, transient ischemic attack, or pulmonary embolism within 12 weeks prior to initiation of momelotinib

... and 7 more (see full listing online)

## Locations (11 total)

---

CHU d'Angers - Service des Maladies du sang, Angers, France  
CHU Estaing - Service d'Hématologie Clinique, Clermont-Ferrand, France  
Hôpital Claude Huriez - Service de Médecine Interne, Lille, France  
... and 8 more locations

---

<https://clinicaltrials.gov/study/NCT07098936>

DISCLAIMER: This document is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before enrolling in any clinical trial. Information may not be up to date — verify details at [ClinicalTrials.gov](https://clinicaltrials.gov). Generated by [ClinicalTrialsFinder.org](https://clinicaltrialsfinder.org).